Related Experiment Video

Updated: Apr 29, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

1.4K

Targeted agents: management of dermatologic toxicities

Barbara Burtness1

  • 1Presented by Barbara Burtness, MD, Clinical Research Program Leader of the Head and Neck Cancers Program, Smilow Cancer Hospital at Yale-New Haven, and Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 24, 2014
PubMed

Insights

Targeted cancer therapies like epidermal growth factor receptor (EGFR) inhibitors can cause prominent skin side effects. Management focuses on improving these cutaneous complications to maintain anticancer treatment.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Targeted cancer therapies, including epidermal growth factor receptor (EGFR) inhibitors, BRAF, and mTOR inhibitors, are associated with significant cutaneous toxicity.
  • Dermatologic side effects are a common and prominent concern in patients undergoing treatment with these agents.

Discussion:

  • Dr. Barbara Burtness highlighted common skin complications from targeted therapies at the NCCN 19th Annual Conference.
  • Strategies for managing skin toxicities include prophylactic and reactive approaches, emphasizing local measures for quality of life.
  • Key interventions involve topical and oral antibiotics and topical steroids to address infections and cosmetic issues.

Key Insights:

  • Cutaneous toxicities from targeted therapies require proactive and reactive management strategies.
  • Improving skin complications is crucial for patient quality of life and adherence to cancer treatment.
  • Early intervention with antibiotics and steroids can effectively manage common dermatologic side effects.

Outlook:

  • Further research into optimizing the management of therapy-induced skin conditions is warranted.
  • Developing standardized protocols for managing cutaneous side effects can improve patient outcomes.
  • Continued focus on supportive care is essential to minimize treatment interruptions due to skin toxicity.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
206
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
271
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
229